首页> 外文期刊>Microcirculation: The official journal of the Microcirculatory Society >Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.
【24h】

Influence of glucose control and improvement of insulin resistance on microvascular blood flow and endothelial function in patients with diabetes mellitus type 2.

机译:血糖控制和胰岛素抵抗的改善对2型糖尿病患者微血管血流量和内皮功能的影响

获取原文
获取原文并翻译 | 示例
           

摘要

OBJECTIVE: The study was performed to investigate the effect of improving metabolic control with pioglitazone in comparison to glimepiride on microvascular function in patients with diabetes mellitus type 2. METHODS: A total of 179 patients were recruited and randomly assigned to one treatment group. Metabolic control (HbA1c), insulin resistance (HOMA index), and microvascular function (laser Doppler fluxmetry) were observed at baseline and after 3 and 6 months. RESULTS: HbA1c improved in both treatment arms (pioglitazone: 7.52 +/- 0.85% to 6.71 +/- 0.89%, p < .0001; glimepiride: 7.44 +/- 0.89% to 6.83 +/- 0.85%, p < .0001). Insulin-resistance decreased significantly in the pioglitazone group (6.15 +/- 4.05 to 3.85 +/- 1.92, p < .0001) and remained unchanged in the glimepiride group. The microvascular response to heat significantly improved in both treatment groups (pioglitazone 48.5 [15.2; 91.8] to 88.8 [57.6; 124.1] arbitrary units [AU], p < .0001; glimepiride 53.7 [14.1; 91.9] to 87.9 [52.9, 131.0] AU, p < .0001, median [lower and upper quartile]). Endothelial function as measured with the acetylcholine response improved in the pioglitazone group (38.5 [22.2; 68.0] to 60.2 [36.9; 82.8], p = .0427) and remained unchanged in the glimepiride group. CONCLUSIONS: Improving metabolic control has beneficial effects in microvascular function in type 2 diabetic patients. Treatment of type 2 diabetic patients with pioglitazone exerts additional effects on endothelial function beyond metabolic control.
机译:目的:本研究旨在探讨吡格列酮与格列美脲相比对2型糖尿病患者改善微血管控制对微血管功能的影响。方法:共招募179例患者,并将其随机分为一个治疗组。在基线以及3个月和6个月后,观察到了代谢控制(HbA1c),胰岛素抵抗(HOMA指数)和微血管功能(激光多普勒通量法)。结果:两个治疗组的HbA1c均得到改善(吡格列酮:7.52 +/- 0.85%至6.71 +/- 0.89%,p <.0001;格列美脲:7.44 +/- 0.89%至6.83 +/- 0.85%,p <.0001 )。吡格列酮组的胰岛素抵抗显着降低(6.15 +/- 4.05至3.85 +/- 1.92,p <.0001),而格列美脲组则保持不变。在两个治疗组中,微血管对热的反应显着改善(吡格列酮48.5 [15.2; 91.8]至88.8 [57.6; 124.1]任意单位[AU],p <.0001;格列美脲53.7 [14.1; 91.9]至87.9 [52.9,131.0] ] AU,p <.0001,中位数[上下四分位数])。在吡格列酮组中,通过乙酰胆碱反应测得的内皮功能得到改善(38.5 [22.2; 68.0]至60.2 [36.9; 82.8],p = .0427),在格列美脲组中保持不变。结论:改善代谢控制对2型糖尿病患者的微血管功能具有有益作用。吡格列酮对2型糖尿病患者的治疗对血管内皮功能的影响超出代谢控制范围。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号